The prognostic significance of ERCC1, BRCA1, XRCC1, and βIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 478-483

  Kang, Chang Hyun ^a   Jang, Bo Gun ^a   Kim, Dong Wan ^a   Chung, Doo Hyun ^a   Kim, Young Tae ^a   Jheon, Sanghoon ^b   Sung, Sook Whan ^b   Kim, Joo Hyun ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

BRCA1; Carcinoma, non small cell; Chemotherapy, neoadjuvant; Drug resistance, neoplasm; ERCC1; Thoracic surgical procedure; Type III tubulin; XRCC1

Indexed keywords

BETA TUBULIN; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DNA; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; XRCC1 PROTEIN; BRIDGED COMPOUND; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TAXANE; TAXOID; TUBB3 PROTEIN, HUMAN; TUBULIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA REPAIR; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SURVIVAL;

ADULT; AGED; BRCA1 PROTEIN; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PLATINUM COMPOUNDS; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TAXOIDS; TUBULIN;

EID: 77952544071     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.004     Document Type: Article

References (30)

1. Felip E., Vilar E. The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. Ann Oncol 2006, 17:108-112.
2. De Marinis F., Tedesco B., Treggiari S., De Santis S., Cipri A., Belli R., et al. Role of induction chemotherapy in resectable N2 non-small cell lung cancer. J Thorac Oncol 2007, 2:S31-S34.
3. Burfeind W.R., Harpole D.H. Surgical strategies and outcomes after induction therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2005, 17:186-190.
4. Betticher D.C., Hsu Schmitz S.F., Totsch M., Hansen E., Joss C., von Briel C., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003, 21:1752-1759.
5. Choi I.S., Oh D.Y., Kwon J.H., Kim S.I., Park S.R., Bak J.Y., et al. Paclitaxel/platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:6-12.
6. Depierre A., Milleron B., Moro-Sibilot D., Chevret S., Quoix E., Lebeau B., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002, 20:247-253.
7. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
8. Rosell R., Cecere F., Santarpia M., Reguart N., Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006, 6:323-331.
9. Breen D., Barlesi F. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg 2008, 33:805-811.
10. Rosell R., Mendez P., Isla D., Taron M. Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007, 2:1063-1066.
11. McGrogan B.T., Gilmartin B., Carney D.N., McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008, 1785:96-132.
12. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004, 4:253-265.
13. Fujii T., Toyooka S., Ichimura K., Fujiwara Y., Hotta K., Soh J., et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008, 59:377-384.
14. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005, 50:211-219.
15. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
16. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
17. Seve P., Isaac S., Tredan O., Souquet P.J., Pacheco Y., Perol M., et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005, 11:5481-5486.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
19. Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Canto A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994, 330:153-158.
20. Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam J.B., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994, 86:673-680.
21. Nagai K., Tsuchiya R., Mori T., Tada H., Ichinose Y., Koike T., et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003, 125:254-260.
22. Rigas J.R., Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:S77-S85.
23. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-2449.
24. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
25. Rosell R., Felip E., Taron M., Majo J., Mendez P., Sanchez-Ronco M., et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004, 10:4215s-4219s.
26. Gazdar A.F. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 2007, 356:771-773.
27. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002, 2:1-17.
28. Seve P., Mackey J., Isaac S., Tredan O., Souquet P.J., Perol M., et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005, 4:2001-2007.
29. Rosell R., Scagliotti G., Danenberg K.D., Lord R.V., Bepler G., Novello S., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003, 22:3548-3553.
30. Wang L., Wei J., Qian X., Yin H., Zhao Y., Yu L., et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8:97.